Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–9 of 9 results
Advanced filters: Author: "Fabien Zoulim" Clear advanced filters

  • Viral hepatitis is a global public health problem. In this Viewpoint, we asked a selection of scientists and clinicians working in the viral hepatitis field to provide their opinions on progress and pitfalls towards the 2030 viral hepatitis elimination goals.

    • Andrea L. Cox
    • Manal H. El-Sayed
    • Fabien Zoulim
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 17, P: 533-542

  • The many gaps in our knowledge and understanding of HBV infection hampers our ability to develop and achieve a cure on a global scale. In this Perspective, Fabien Zoulim and colleagues propose the development of an international group consisting of four working groups (virology, immunology, innovative tools and clinical trials) to tackle the big questions and make important steps towards eradicating this disease.

    • Peter Revill
    • Barbara Testoni
    • Fabien Zoulim
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 13, P: 239-248

  • This Poster illustrates the current epidemiology, clinical management and novel treatment targets of hepatitis B, a disease responsible for a large global burden of liver cirrhosis and cancer.

    • Fabien Zoulim
    • Massimo Levrero
    • Barbara Testoni
    Multimedia
    Nature Reviews Gastroenterology & Hepatology
    P: 1

  • Hepatitis B virus (HBV) core protein-targeting compounds are in or entering clinical development without a standardized nomenclature. We propose a naming convention for these core-targeting antiviral products to provide clarity and accelerate HBV drug development.

    • Fabien Zoulim
    • Adam Zlotnick
    • Harry L. A. Janssen
    Comments & Opinion
    Nature Reviews Gastroenterology & Hepatology
    Volume: 19, P: 748-750

  • The failure of antiviral therapy for chronic hepatitis B can involve both virological breakthrough and genotypic resistance. A study of the failure of nucleoside analogue therapy suggests that drug-resistant mutants are not solely responsible for treatment failure. Suboptimal treatment adherence might also have an important role.

    • Fabien Zoulim
    News & Views
    Nature Reviews Gastroenterology & Hepatology
    Volume: 8, P: 366-367

  • Nucleoside analogues have been in clinical use for many years, but there are ongoing efforts to improve patient response rates and reduce side effects. Here, the authors highlight recent progress in the development of new nucleoside and nucleotide analogues for the treatment of cancer and viral diseases.

    • Lars Petter Jordheim
    • David Durantel
    • Charles Dumontet
    Reviews
    Nature Reviews Drug Discovery
    Volume: 12, P: 447-464

  • Insights into the life cycle of hepatitis C virus (HCV) have facilitated the development of a number of innovative agents. Here, Manns and colleagues discuss the obstacles in current HCV management, the key challenges for new HCV antivirals and potential future therapeutic options.

    • Michael P. Manns
    • Graham R. Foster
    • Michael Houghton
    Reviews
    Nature Reviews Drug Discovery
    Volume: 6, P: 991-1000

  • Current treatments efficiently control chronic HBV infection but they do not lead to its elimination. Now, Ebert and colleagues have shown that cellular inhibitor of apoptosis proteins (cIAPs) prevent TNF-mediated killing of infected hepatocytes and that cIAP antagonists might lead to HBV cure by promoting death of infected cells.

    • Julie Lucifora
    • Christian Trepo
    News & Views
    Nature Reviews Gastroenterology & Hepatology
    Volume: 12, P: 376-378